Topical drug delivery composition and method
AssigneeMedicis Pharmaceutical Corporation
InventorsThomas P. Nigra, Eugene H. Gans
Life of this patent
Estimating the term…
Abstract
A topical composition for delivering an effective amount of a pharmaceutically acceptable drug, including laureth-4, propylene glycol, dimethylsorbide, and a pharmaceutically acceptable diluent is described as an improved drug delivery composition. Further, a method of transepithelial delivery of a drug to a human by topical application to the skin of a human of a composition including laureth-4, propylene glycol, dimethylsorbide, a pharmaceutically acceptable diluent of water and ethanol and an effective amount of a pharmaceutically acceptable drug has beneficial delivery effects.
Claims74
A topical composition comprising:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) trans-retinoic acid, present in about 0.01 percent by weight of the total composition;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transepithelial delivery of trans-retinoic acid to a human, comprising applying to the skin of the human a topical composition comprising:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) trans-retinoic acid, present in about 0.01 percent by weight of the total composition;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A topical composition comprising:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transepithelial delivery of a drug to a human, comprising applying to the skin of the human a topical composition comprising:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A topical composition comprising:
- i) SDA-40 200 proof, present in about 36.8 percent by weight of the total composition;
- ii) butylated hydroxyanisole, present in about 0.15 percent by weight of the total composition;
- iii) glycerin, present in about 2 percent by weight of the total composition;
- iv) propylene glycol, present in about 2 percent by weight of the total composition;
- v) purified distilled water, present in about 40 percent by weight of the total composition;
- vi) pantethine, present in about 0.03 percent by weight of the total composition;
- vii) laureth-4, present in about 1 percent by weight of the total composition;
- viii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- ix) disodium EDTA, present in about 0.15 percent by weight of the total composition;
- and
- x) distilled water.
A method for transepithelial delivery of a drug to a human, comprising applying to the skin of the human a topical composition comprising:
- i) SDA-40 200 proof, present in about 36.8 percent by weight of the total composition;
- ii) butylated hydroxyanisole, present in about 0.15 percent by weight of the total composition;
- iii) glycerin USP 96 percent, present in about 2 percent by weight of the total composition;
- iv) propylene glycol, present in about 2 percent by weight of the total composition;
- v) purified distilled water, present in about 40 percent by weight of the total composition;
- vi) pantethine 80 percent, present in about 0.03 percent by weight of the total composition;
- vii) laureth-4, present in about 1 percent by weight of the total composition;
- viii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- ix) disodium EDTA present in about 0.15 percent by weight of the total composition;
- x) a pharmaceutically active drug, wherein the drug is effective when administered topically;
- and
- xi) distilled water.
A topical composition comprising:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) a dermally active ingredient, present in about 0.01 percent by weight of the total composition;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transepithelial delivery of a dermally active ingredient to a human, comprising applying to the skin of the human a topical composition comprising:
- i) laureth-4, present in about 1 percent by weight of the total composition;
- ii) propylene glycol, present in about 2 percent by weight of the total composition;
- iii) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- iv) a dermally active ingredient, present in about 0.01 percent by weight of the total composition;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A topical composition comprising:
- i) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride;
- ii) propylene glycol;
- iii) dimethylsorbide;
- iv) trans-retinoic acid;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transdermal delivery of trans-retinoic acid to a human, comprising applying to the skin of the human a topical composition comprising:
- i) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride;
- ii) propylene glycol;
- iii) dimethylsorbide;
- iv) trans-retinoic acid;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transepithelial delivery of trans-retinoic acid to a human, comprising applying to the skin of the human a topical composition comprising:
- a) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride;
- b) propylene glycol;
- c) dimethylsorbide;
- d) trans-retinoic acid;
- and
- e) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A topical composition comprising:
- a) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride;
- b) propylene glycol;
- c) dimethylsorbide;
- d) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically;
- and
- e) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transdermal delivery of a drug to a human, comprising applying to the skin of the human a topical composition comprising:
- a) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride;
- b) propylene glycol;
- c) dimethylsorbide;
- d) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically;
- and
- e) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transepithelial delivery of a drug to a human, comprising applying to the skin of the human a topical composition comprising:
- a) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride;
- b) propylene glycol;
- c) dimethylsorbide;
- d) an effective amount of a pharmaceutically acceptable drug, wherein the drug is effective when administered topically;
- and
- e) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transdermal delivery of a dermally active ingredient to a human, comprising applying to the skin of the human a topical composition comprising:
- a) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride, present in about 1 percent by weight of the total composition;
- b) propylene glycol, present in about 2 percent by weight of the total composition;
- c) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- d) a dermally active ingredient, present in about 0.01 percent by weight of the total composition;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
A method for transepithelial delivery of a dermally active ingredient to a human, comprising applying to the skin of the human a topical composition comprising:
- a) One or more pharmaceutically acceptable surface tension reducing agents selected from the group consisting of laureth-4, octoxynol-9, cocamphocarboxyglycinate, dioctyl sodium sulfosuccinate and benzethonium chloride, present in about 1 percent by weight of the total composition;
- b) propylene glycol, present in about 2 percent by weight of the total composition;
- c) dimethylsorbide, present in about 0.5 percent by weight of the total composition;
- d) a dermally active ingredient, present in about 0.01 percent by weight of the total composition;
- and
- v) a pharmaceutically acceptable diluent comprising a mixture of water and ethanol.
Dependencies are inferred from the claim text.